ESC Congress 2026 Abstract
Dapagliflozin did not clearly improve exercise capacity
Peak oxygen use was an adjusted 0.67 milliliters per kilogram per minute lower with dapagliflozin than placebo in stable, symptomatic pulmonary arterial or chronic…Peak oxygen use was an adjusted 0.67 milliliters per kilogram per minute lower with dapagliflozin than placebo in stable, symptomatic pulmonary arterial or chronic thromboembolic pulmonary hypertension.
Randomized trial · 52 peopleDapagliflozin
Who was studied52 patients with stable PAH and CTEPH, 12 weeks, against placebo
What changedPeak VO2 did not differ with dapagliflozin against placebo: adjusted mean difference -0.67 mL/kg/min (95% CI [-1.67, 0.33])
The catchOnly 52 patients were randomized in the trial